Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

p53, a potential target for tumor-directed T cells

H W Nijman¹, S H Van der Burg, M P Vierboom

¹Department of Immunohaematology and Blood Bank, University Hospital, Leiden, The Netherlands.

Immunology Letters

|May 1, 1994

Summary

Researchers identified specific wild-type p53 peptides that bind strongly to HLA-A*0201, leading to the generation of cytotoxic T lymphocyte (CTL) responses. These findings support targeting p53 for cancer immunotherapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Local immunosuppressive microenvironment underlies reduced responsiveness to imiquimod treatment in recurrent or residual cervical HSIL.

Gynecologic oncology reports·2026

Same author

Changes in bone marrow fat fraction and immune cell counts in women with cervical cancer treated with primary chemoradiotherapy.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2025

Same author

Dataset from a proteomics analysis of tumor antigens shared between an allogenic tumor cell lysate vaccine and pancreatic tumor tissue.

Data in brief·2022

Same author

Autologous dendritic cells pulsed with allogeneic tumour cell lysate induce tumour-reactive T-cell responses in patients with pancreatic cancer: A phase I study.

European journal of cancer (Oxford, England : 1990)·2022

Same author

Prognostic image-based quantification of CD8CD103 T cell subsets in high-grade serous ovarian cancer patients.

Oncoimmunology·2021

Same author

Melanoma cells can be eliminated by sialylated CD43 × CD3 bispecific T cell engager formats in vitro and in vivo.

Cancer immunology, immunotherapy : CII·2020

Area of Science:

Immunology
Oncology
Molecular Biology

Background:

Tumor-specific antigens can trigger cytotoxic T lymphocyte (CTL) responses, offering a basis for cancer immunotherapy.
Self-proteins like p53 are potential targets for T cell-mediated anti-cancer immunity, as suggested by responses to melanoma-associated antigens.
Identifying specific epitopes is crucial for developing p53-targeted T cell therapies.

Purpose of the Study:

To identify wild-type p53 peptides with high affinity for the HLA-A*0201 molecule.
To generate and characterize CTL responses against these p53 peptides.

Main Methods:

Utilized MHC peptide-binding and peptide competition assays to screen p53 peptides for HLA-A*0201 binding affinity.
Generated CTLs specific for high-affinity p53 peptides.

Related Experiment Videos

Main Results:

Identified several wild-type p53 peptides exhibiting high affinity for the HLA-A*0201 molecule.
Successfully generated CTLs recognizing four high-affinity p53 peptides.

Conclusions:

The study successfully identified p53-derived peptides that can elicit CTL responses in the context of HLA-A*0201.
These findings provide a foundation for developing novel cancer immunotherapies targeting wild-type p53.